Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2012 | 10:28pm CET

CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH CORP
02/25 CVS HEALTH : to close 11 Chicago stores by late March
02/24 CVS HEALTH : And Breathe California Announce Statewide Finalists In Student Film..
02/22 CVS HEALTH : Pharmacy Is First National Retail Pharmacy to Remove Artificial Tra..
02/20 CVS HEALTH : president says big changes underway in pharmacy
02/17 IT HAS WORKED : CVS Health Corp (NYSE:CVS) Says Of Its Exit Of Cigarette Busines..
02/17 CVS : Restricting Access to Cigarettes can positively Impact Public Health
02/17 CVS HEALTH : Maintaining Quality and Improving Outcomes during Care Transitions
02/17 CVS HEALTH : FORTUNE Recognizes CVS Health on List of 'World's Most Admired Comp..
02/16 CVS HEALTH : Research Institute Study Confirms that the Company's Tobacco Remova..
02/16 CVS HEALTH : FORTUNE Recognizes CVS Health on List of "World's Most Admired Comp..
More news
Sector news : Drug Retailers - NEC
02/16DJRetail CEOs Meet With Trump Over Border Tax Concerns -- Update
02/15DJRetail CEOs Meet With Trump Over Border Tax Concerns
02/14DJEXPRESS SCRIPTS : Revenue Falls
02/14 Exclusive - Trump to meet with retail CEOs on taxes, infrastructure
02/09DJCVS HEALTH : Profit Rises, Helped by Pharmacy Strength -- Update
More sector news : Drug Retailers - NEC
News from SeekingAlpha
02/27 MANNKIND : Empty Saddles And Empty Promises
02/27 My Portfolio Now Has 15 Consumer Staples Defensive Sector Stocks After Adding..
02/25 MARKETPLACE ROUNDTABLE : Prices Are Going Up, But Dividends Keep Coming
02/24 Rite Aid Investors Should Take A Hard Look The Walgreens Merger Valuation Bef..
02/24 Is It Time To Sell Everything But High Quality Stocks?
Financials ($)
Sales 2017 184 356 M
EBIT 2017 10 398 M
Net income 2017 5 637 M
Debt 2017 24 997 M
Yield 2017 2,35%
P/E ratio 2017 15,40
P/E ratio 2018 13,79
EV / Sales 2017 0,59x
EV / Sales 2018 0,56x
Capitalization 83 574 M
More Financials
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 86,3 $
Spread / Average Target 6,0%
Consensus details
EPS Revisions
More Estimates Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP3.26%83 574
More Results